Biocon Limited announced that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide (6mg/ml solution for injection in pre-filled pen), which was filed through its European partner, Zentiva. Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus, a disorder in which the body does not produce enough or respond normally to insulin, causing blood sugar (glucose) levels to be abnormally high.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
316.7 INR | -0.33% | +2.87% | +26.90% |
May. 24 | INDIA STOCKS-Indian shares surrender gains as U.S. rate worries weigh | RE |
May. 24 | Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.90% | 4.56B | |
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-1.69% | 21.83B | |
-10.23% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Biocon Limited to Obtain Approval for Diabetes Drug, Liraglutide, in the U.K